Competitive Landscape

Top companies in the antibodies market are focusing on advancing their research and fast-tracking the development of new antibodies to launch new products and gain a competitive advantage over other market players.

• On September 19, 2022, Sandoz, a leader in biosimilars and generic pharmaceuticals, announced the progress of its biosimilar pipeline. This included positive results for the proposed biosimilar denosumab from ROSALIA Phase I/III clinical trial study. Denosumab is a human monoclonal antibody designed to bind and inhibit RANKL to reduce bone loss.

Leading suppliers of antibodies are also eyeing partnerships, collaborations, and mergers to increase their market presence and widen their research scope.

• In March 2022, Sanofi, a leading pharmaceutical organization announced that it will partner with IGM Biosciences to create, develop, manufacture, and commercialize six new immunoglobulin M antibody agonists. Through this partnership, Sanofi has committed to over US$ 6 billion in potential milestone payments.

Key Segments in Antibodies Industry Research

• By Product Type :

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Immune Checkpoint Antibodies
  • Epitope Tag Antibodies
  • Isotype Control Antibodies
  • Primary Antibodies
  • Assay Antibodies
  • Others

• By Application :

  • Drug Discovery & Development
  • Basic Research
  • Toxicity Screening
  • Biopharmaceutical Production
  • Drug Screening
  • Tissue Engineering
  • Forensic Testing
  • Others

• By End User :

  • Biopharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Forensic Science Laboratories
  • Food & Beverage Companies
  • Diagnostic Centers
  • Others

• By Region :

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA